Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + doxorubicin + vincristine + prednisone
- Development stage
- Unknown
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
CHOP is a combination chemotherapy regimen consisting of four drugs: cyclophosphamide, doxorubicin, vincristine, and prednisone. Cyclophosphamide is an alkylating agent that interferes with DNA replication in rapidly dividing cells. Doxorubicin is an anti-tumor antibiotic that intercalates into DNA and inhibits topoisomerase II, leading to DNA damage and cell death. Vincristine is a plant alkaloid that disrupts microtubule formation during cell division. Prednisone is a synthetic glucocorticoid steroid that induces apoptosis in certain cancer cells and has anti-inflammatory effects. CHOP is primarily used as first-line treatment for non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, and other lymphoid malignancies[1][2][3][4]. The regimen works by targeting multiple pathways essential for cancer cell survival and proliferation.
- Brand names
- None
- Other names
- None
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNAGR (Glucocorticoid receptor)
Beyond the preview
Go deeper on cyclophosphamide + doxorubicin + vincristine + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + doxorubicin + vincristine + prednisone.